November 08, 2016
Cerenis Therapeutics Announces Last Patient Dosed in CARAT Phase II Study with CER-001 in Post-Acute Coronary Syndrome Patients
Media
November 07, 2016
Coverage regarding Targovax’s presentation at ESGCT/ISSCR Stem Cells & Gene Therapy Symposium
November 07, 2016
Cash position and revenue for Q3 2016
November 04, 2016
Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer
November 04, 2016
Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®
November 03, 2016
Results from preclinical studies of Betalutin® in combination with rituximab in non-Hodgkin lymphoma model to be presented at ASH
November 03, 2016
Updated results from Phase 1/2 trial of Betalutin® in non-Hodgkin lymphoma to be presented at ASH annual meeting in December
November 03, 2016
Q3 2016 General Market Overview
November 02, 2016
Targovax announces appointment of Oystein Soug as CEO
October 28, 2016
Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors
